<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tenapanor: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tenapanor: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tenapanor: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="122583" href="/d/html/122583.html" rel="external">see "Tenapanor: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F56785178"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of serious dehydration in pediatric patients (Ibsrela only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tenapanor is contraindicated in patients &lt;6 years of age; in nonclinical studies in young juvenile rats, administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of tenapanor in patients 6 to &lt;12 years of age. The safety and effectiveness of tenapanor have not been established in patients &lt;18 years of age.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56663746"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ibsrela;</li>
<li>Xphozah</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55189589"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ibsrela</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53649739"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F54086754"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="260f20d5-597c-46c0-b39a-7bd210352f76">Hyperphosphatemia in chronic kidney disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperphosphatemia in chronic kidney disease, treatment (Xphozah):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use as an add-on therapy in patients on dialysis who have an inadequate response to phosphate binders or who are unable to tolerate phosphate binder therapies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Usual dose: 30 mg twice daily; may decrease dose if needed based on serum phosphate concentration and GI tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35372979','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35372979','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9895d84-f23d-4ab8-b478-fe854563cc86">Irritable bowel syndrome with constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome with constipation (Ibsrela):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients in whom other therapies for constipation have failed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 50 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33337659','lexi-content-ref-28244495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33337659','lexi-content-ref-28244495'])">Ref</a></span>). Some experts consider alternative therapy in patients without improvement by 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wald.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F54088556"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment is unlikely due to low systemic absorption and minimal renal excretion of tenapanor. For patients on hemodialysis, do not administer immediately before a hemodialysis session; administer prior to the next meal following dialysis.</p></div>
<div class="block doha drugH1Div" id="F54088557"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment is unlikely due to low systemic absorption.</p></div>
<div class="block dot drugH1Div" id="F54088558"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Severe diarrhea: Discontinue treatment.</p></div>
<div class="block doe drugH1Div" id="F54086755"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F53660795"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (15% to 53%; severe diarrhea: 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (2% to 3%), abnormal bowel sounds (&lt;2%), flatulence (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Rectal hemorrhage (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (2%)</p></div>
<div class="block coi drugH1Div" id="F53646341"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Patients &lt;6 years of age; known or suspected mechanical GI obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to tenapanor or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54086744"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Diarrhea: May cause diarrhea (including severe cases).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: May increase the risk for adverse reactions, including diarrhea and hyperkalemia (requiring hospitalization).</p></div>
<div class="block foc drugH1Div" id="F56663747"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibsrela: 50 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xphozah: 20 mg, 30 mg</p></div>
<div class="block geq drugH1Div" id="F55189587"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56695222"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ibsrela Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $35.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Xphozah Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $59.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $59.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55189590"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ibsrela: 50 mg</p></div>
<div class="block adm drugH1Div" id="F54088559"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer immediately prior to breakfast or the first meal of the day and immediately prior to dinner. When using to control phosphorus concentrations in patients on dialysis, do <b>not</b> administer right before a hemodialysis session, and instead administer prior to the next meal following dialysis.</p></div>
<div class="block meg drugH1Div" id="F56790883"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">Ibsrela: An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F211801s004lbl.pdf%23page%3D14&amp;token=iv3xw88mBVkYvnNhWzzelZ%2B3PVgUn56z6sO3gxgkk2r%2FXWqknXZgSrNxzqb9qhI7%2FuE2Aff8kh5vwxQbkdj%2BC58zG%2B%2B2oGckRSRj2luVnZvX5nesB717c1qnadzijXob&amp;TOPIC_ID=122582" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211801s004lbl.pdf#page=14</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F53646340"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperphosphatemia in chronic kidney disease, treatment (Xphozah): </b>Control of serum phosphorous in adults with chronic kidney disease on hemodialysis. Use as an add-on therapy in patients who have an inadequate response to phosphate binders or who are unable to tolerate phosphate binder therapies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome with constipation (Ibsrela):</b> Treatment of irritable bowel syndrome with constipation in adults.</p></div>
<div class="block cyt drugH1Div" id="F53659135"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F53659132"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Enalapril: Tenapanor may decrease serum concentrations of the active metabolite(s) of Enalapril. Tenapanor may decrease the serum concentration of Enalapril. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: May diminish the therapeutic effect of Tenapanor. Management: Separate administration of tenapanor and sodium polystyrene sulfonate (SPS) by at least 3 hours.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F54086746"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration 5 to 10 minutes before a meal increased the 24-hour stool sodium excretion compared to administration in the fasting state.</p></div>
<div class="block pri drugH1Div" id="F54086742"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Patients who could become pregnant were not included in the initial clinical trials (Chey 2020). Tenapanor has limited systemic absorption following oral administration. Use during pregnancy is not expected to result in significant exposure to the fetus.</p></div>
<div class="block brc drugH1Div" id="F54086743"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tenapanor is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Tenapanor has limited systemic absorption following oral administration; clinically relevant exposure via breast milk is not expected. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F54088561"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Frequency of bowel movements; signs and symptoms of dehydration in patients with diarrhea; serum potassium in patients with renal impairment; serum phosphorus.</p></div>
<div class="block pha drugH1Div" id="F54086748"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Tenapanor is a sodium/hydrogen exchanger 3 inhibitor, which acts locally to reduce sodium absorption from the small intestine and colon. Reduced sodium absorption results in increased intestinal lumen water secretion, accelerating intestinal transit time, and softening stool consistency. Tenapanor also decreases intestinal permeability and visceral hypersensitivity in animal models, which may reduce abdominal pain.</p>
<p style="text-indent:-2em;margin-left:2em;">Additionally, tenapanor decreases the absorption of phosphate. The inhibition of the sodium/hydrogen exchanger 3 increases the proton concentration in the cells lining the GI lumen causing a conformational change in tight junction proteins and decreasing paracellular phosphate transport from the intestinal lumen (Block 2021).</p></div>
<div class="block phk drugH1Div" id="F54086749"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Minimal.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4/5 primarily to inactive metabolite M1.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~79% as unchanged drug); urine (~9% as metabolites).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35372979">
<a name="35372979"></a>Block GA, Bleyer AJ, Silva AL, et al. Safety and efficacy of tenapanor for long-term serum phosphate control in maintenance dialysis: a 52-week randomized phase 3 trial (PHREEDOM). <i>Kidney360.</i> 2021;2(10):1600-1610. doi:10.34067/KID.0002002021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenapanor-drug-information/abstract-text/35372979/pubmed" id="35372979" target="_blank">35372979</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). <i>Am J Gastroenterol</i>. 2020;115(2):281-293. doi:10.14309/ajg.0000000000000516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenapanor-drug-information/abstract-text/31934897/pubmed" id="31934897" target="_blank">31934897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28244495">
<a name="28244495"></a>Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. <i>Am J Gastroenterol</i>. 2017;112(5):763-774. doi:10.1038/ajg.2017.41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenapanor-drug-information/abstract-text/28244495/pubmed" id="28244495" target="_blank">28244495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33337659">
<a name="33337659"></a>Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). <i>Am J Gastroenterol</i>. 2021;116(6):1294-1303. doi:10.14309/ajg.0000000000001056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tenapanor-drug-information/abstract-text/33337659/pubmed" id="33337659" target="_blank">33337659</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ibsrela (tenapanor) [prescribing information]. Waltham, MA: Ardelyx Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ibsrela.2">
<a name="Ibsrela.2"></a>Ibsrela (tenapanor) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.1">
<a name="Wald.1"></a>Wald A. Treatment of irritable bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 25, 2022.</div>
</li>
<li>
<div class="reference">
                  Xphozah (tenapanor) [prescribing information]. Waltham, MA: Ardelyx Inc; October 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 122582 Version 63.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
